Install
DocWire News delivers the latest health care news, research, and trends in medicine, giving health care professionals access to the curated content most relevant to their fields.
- 61articles · 30d
- 1+ day agolatest article
- Aug 17, 2026earliest in window
- 97%with images
- 264avg words
- Health & Wellness 61
- Medical 58
- Health 56
- Education 2
- Finance & Business 2
- Economy, Business & Finance 1
- Labour 1
- Politics 1
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Endocrine Therapy for ESR1-Mutated Metastatic Breast Cancer
1+ day, 17+ hour ago (216+ words) In the first segment of this roundtable series, the panel discusses the current treatment landscape, how it has evolved with new approvals and data, ongoing trials, and what might be on the horizon for patients with ESR1-mutated disease in the…...
Updates in Melanoma From ASCO
3+ day, 12+ hour ago (379+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates in melanoma presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Meredith McKean, MD, MPH: Hi, I am Meredith McKean. I’m a…...
Updates to Merkel Cell Carcinoma From ASCO
3+ day, 12+ hour ago (320+ words) Meredith McKean, MD, MPH, of Sarah Cannon Research Institute in Nashville, Tennessee, shares commentary on updates to Merkel cell carcinoma (MCC) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. McKean describes updates from the STAMP, ADAM, and…...
Biparatopic HER2 Targeting in Action: Anbenitamab???s Phase 3 Breakthrough
3+ day, 12+ hour ago (38+ words) Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Docwire News Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Shao ZM, et al. Basch E, et al. 2026 American Society of Clinical Oncology Annual Meeting. Abstract LBA660....
Five-Year PHERGain Results Validate pCR-Guided Treatment De-Escalation
3+ day, 12+ hour ago (136+ words) Docwire News Five-Year PHERGain Results Validate pCR-Guided Treatment De-Escalation According to Dr. Antonio Llombart-Cussac, the 5-year PHERGain analysis confirms the long-term safety and effectiveness of a chemotherapy-sparing, response-guided approach in HER2-positive breast cancer, with approximately 91% invasive disease-free survival across the…...
Can Acetylcholine Receptor Antibody Profiling Predict FcRn Therapy Outcomes in MG?
3+ day, 12+ hour ago (296+ words) Dr. Iorio: My name is Raffaele Iorio. I’m an associate professor of neurology at the Universita Cattolica del Sacro Cuore in Rome, Italy. I am also a staff neurologist at the Fondazione Policlinico Gemelli in Rome, Italy. Rare Diseases Today:…...
Can We Add Upadacitinib to the Alopecia Areata Arsenal?
2+ week, 4+ day ago (689+ words) Docwire News Upadacitinib Shows Promising Efficacy for Alopecia Areata According to phase 3 data, upadacitinib may represent a potential treatment option for patients with severe alopecia areata. There is currently an unmet need for systemic therapies for alopecia areata—with only…...
Phase 3 LUCIDITY Trial Success Puts Avexitide on Track to Become First PBH Treatment
3+ week, 7+ hour ago (260+ words) PBH is a chronic metabolic condition that affects about 8% of people in the US following sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB) surgery, the two most common types of bariatric surgery. The condition can cause severe hypoglycemia, leading to substantial…...